Patent: 10,017,492
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,017,492
| Title: | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| Abstract: | Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and inflammatory disease. ##STR00001## |
| Inventor(s): | Ge; Chuansheng (Shanghai, CN), Lee; Wen-Cherng (Shanghai, CN), Liao; Baisong (Shanghai, CN), Zhang; Lei (Shanghai, CN) |
| Assignee: | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) |
| Application Number: | 15/523,651 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,017,492
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2034-10-30 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2034-10-30 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2034-10-30 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | See Plans and Pricing | 2034-10-30 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | See Plans and Pricing | 2034-10-30 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | See Plans and Pricing | 2034-10-30 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | See Plans and Pricing | 2034-10-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
